mRNA tumor vaccine encoding membrane-bound il-12 cytokine adjuvant, and use thereof
CA3322873A1Pending Publication Date: 2026-09-21TSINGHUA UNIVERSITY
0 Cites 0 Cited by
Patent Information
- Application Number
- CA3322873
- Authority / Receiving Office
- CA · CA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-04
- Filing Date
- 2025-03-04
- Publication Date
- 2026-09-21
AI Technical Summary
Technical Problem
Direct injection of existing mRNA tumor vaccine adjuvants such as IL-12 protein causes serious side effects. How to limit IL-12 to peripheral lymphoid tissues without affecting the adjuvant effect, reduce systemic toxicity, and improve the immune effect of tumor vaccines?
Method used
An mRNA tumor vaccine encoding a membrane-bound IL-12 cytokine adjuvant is designed to allow IL-12 to be expressed on the surface of antigen-presenting cells. By adding a cell membrane-anchored IL-12 sequence to the mRNA, the release of IL-12 in peripheral lymphoid tissues is restricted.
Benefits of technology
It significantly improved the therapeutic effect of mRNA tumor vaccines, reduced the systemic toxicity of IL-12 protein, and enhanced the safety and efficacy of anti-tumor immune responses.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure relates to an mRNA tumor vaccine encoding a membrane-tethered IL-12 cytokine adjuvant and uses thereof, which reduces IL-12 toxicity and improves the therapeutic efficacy of the mRNA tumor vaccine. The mRNA comprises three components: an IL-12-encoding sequence (IL12), a membrane-domain-encoding sequence (MD), and a tumor-antigen-encoding sequence (Ag).
Need to check novelty before this filing date? Find Prior Art